Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25195535 | 1.00 | FOLH1 (0.78) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL22712857 | 0.96 | FOLH1 (0.72) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL14729505 | 0.96 | FOLH1 (0.72) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL25197245 | 0.94 | FOLH1 (0.73) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL25197246 | 0.94 | FOLH1 (0.73) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL22712908 | 0.91 | FOLH1 (0.72) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL14719863 | 0.91 | FOLH1 (0.72) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL14729437 | 0.91 | FOLH1 (0.72) | FOLH1HTTSIRT2SIRT1PTGER4 | |
| SCHEMBL19743088 | 0.90 | FOLH1 (0.92) | FOLH1HTTMMP2MMP9CPB1 | |
| SCHEMBL19743085 | 0.90 | FOLH1 (0.92) | FOLH1HTTMMP2MMP9CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, INSR, IAPP | FOLH1 544/4885HTT 982/4885SIRT2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.